top of page

Why we do what we do

Our mission is to provide comprehensive support to early-phase clinical trials, fostering a strong foundation for research projects that will pave the way for future advancements in healthcare. We are dedicated to collaborating with researchers, clinicians, biotechnology companies and pharmaceutical companies to ensure that every trial is conducted with utmost precision, integrity, and adherence to industry standards. Through our expertise and services, we aim to support the development of safe and effective treatments, contributing to the betterment of human health and the advancement of medical science

2023-05-13 19_57_24.755+1000.jpg

Rachelle Kirk-Burnnand\

  • LinkedIn

Managing Director

Rachelle is a highly experienced clinical trials professional with over 20 years of expertise. She has worked in various roles and organizations, managing global and local clients. Her specialization lies in Early Phase studies, including SAD/MAD, FIH, Biosimilars, Food Effect, and patient cohorts. Rachelle also has extensive experience in Phase II/III studies in multiple therapeutic areas. With strong communication and strategic thinking skills, she excels at working at senior and executive levels. She has a track record of building effective teams, exceeding targets, and managing stakeholder relationships globally. Rachelle is passionate about achieving common goals and delivering results for clients and team members.

Our Expertise 

Early Phase, Phase II and Phase III

  • First in Human

  • SAD/MAD

  • BioSimilar

  • Food Effect 

  • Oncology,

  • Neuroscience,

  • Mental Health

  • Dermatology

  • Vaccines

  • Rare diseases

  • Urology

  • Ophthalmology. 

bottom of page